Results of a cross-sectional study highlight the clinical features shared by bipolar disorder and migraine, and assesses characteristics of patients with both conditions.
Prevalence of migraine is high among those with bipolar disorder (BD) and is associated with a more severe clinical burden, including increased comorbidity with pain and inflammatory conditions, according to results of a cross-sectional study. Findings were published in the Journal of Affective Disorders.
Both BD and migraine are leading causes of disability worldwide, while previous studies have revealed migraine occurs in more than one-third of individuals with BD. “Conversely, patients with migraine have elevated rates of BD, and a family history of BD is a risk factor for migraine development,” the authors wrote.
The courses of BD and migraine also share commonalities, such as recurrent episodic presentations, evening chronotypes, and dietary habits. In addition, cardiometabolic conditions like obesity and hypertension are common in those with BD and migraineurs.
To better understand the clinical correlates, patterns of general medical comorbidities, and treatment of patients with BD and migraine, the researchers assessed the prevalence of migraine in a large sample of patients with BD from the Mayo Clinic Bipolar Disorder Biobank.
All individuals were between the ages 18 and 80, and of the 721 patients with BD identified in the cohort, 207 (29%) self-reported a lifetime history of migraine. Patients with both BD and migraine were significantly younger and more likely to be female than those with just BD (P <.01).
Analyses revealed:
In addition, the authors did not “find a difference in migraine rates between BD subtypes, or an association of migraine with suicidality or comorbid eating or substance use disorders, or cardiometabolic disorders (eg, obesity), as previously reported,” they noted.
The evening chronotype reported by one-third of migraineurs serves as a proxy marker of circadian phase delay associated with adverse health outcomes, suggesting circadian system function may play a role in BD and migraine in a subset of patients.
The cross-sectional nature of the study precludes causal conclusions from being drawn, marking a limitation, while characteristics of migraine were not assessed (frequency, aura, etc).
“Our results highlight the need to implement a systematic assessment for migraine headaches and associated comorbidities in all patients diagnosed with BD as part of routine clinical care. Such an approach could enhance early identification and treatment of the migraine-BD phenotype,” the authors concluded.
“The pattern of general medical comorbidity and associated features that are present in a clearly defined sub-phenotype like the BD and migraine comorbidity may provide insight into their underlying brain-body interaction disturbances, their origins, and progression,” they said.
Reference
Romo-Nava F, Blom T, Cuellar-Barboza A, et al. Revisiting the bipolar disorder with migraine phenotype: clinical features and comorbidity. J Affect Disord. Published online August 23, 2021. doi:10.1016/j.jad.2021.08.026
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen